PolyPid is a clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary Polymer-Lipid Encapsulation matrix (PLEX) technology. Co.'s product candidates are designed to address diseases with unmet medical needs by pairing its PLEX technology with drugs already approved by the U.S. Food and Drug Administration. Co.'s PLEX technology is designed to deliver drugs directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. Co.'s primary product candidate, D-PLEX100, is for abdominal (soft) tissue. The PYPD stock yearly return is shown above.
The yearly return on the PYPD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PYPD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|